Replies to post #267821 on Avid Bioservices Inc (CDMO)

[patientlywaiting]

We really need CP tell us what's good about this PR..........!

[Protector]

jakeDM, Freimark presents the solution, and they know it since two of the 3 below use a vocabulary INTRODUCED by PPHM in relation to increasing the RESPONDERS to I-O therapy with anti-PD.

Edward Cha, M.D., Ph.D., Associate Medical Director, Cancer Immunotherapy Franchise, Genentech

Although targeted inhibition of the PD-L1 pathway enhances anti-tumor immunity, not all patients achieve benefit from single-agent immunotherapies. Determining and prioritizing effective combinations will rely on further understanding of the mechanisms that drive immune resistance across indications and individual patients.

David Kaufman, Ph.D., Executive Director, Clinical Oncology, Merck Research Laboratories

A variety of other agents may have additive or synergistic activity in combination with PD-1 checkpoint blockade. As such regimens advance, it will be critically important to understand how to direct the right combinations to patients who stand to benefit most from them. Next-generation biomarkers are beginning to provide insight into fundamental aspects of tumor cell and immune biology that are relevant for a precision medicine approach to cancer immunotherapy combinations.

Cancer Immunotherapy: Immunomodulatory Approaches Beyond PD-1

Andrea_van_ElsasAndrea van Elsas, Ph.D., CSO, Aduro Biotech Europe, The Netherlands

T cell checkpoint inhibitors set a clinical paradigm providing significant benefit to patients diagnosed with advanced cancer. Despite success, the majority of patients do not respond to PD-1, PD-L1 or CTLA-4 blockade. Raising the number of patients benefiting from cancer immunotherapy requires novel therapeutic approaches aimed at these non-responders, for instance using novel immunomodulatory antibodies and combination with active immunization.

So NOW the industry is opening up for combinations that FILL THEIR COFFERS better, namely increasing responders to I-O anti-PD therapy. PPHM introduced the concept and has test results in I-O to back it up. This means we absolutely should now what the results on humans are with Yervoy.

[stoneroad]

According to Bruce, collaborators have stated PSisno BS. We shall see.